Brief: Simcere Pharmaceutical Says Phase 3 Clinical Study Of Daridorexant Hydrochloride Tablets In China Met Primary Endpoint
31/05/2024 15:43
May 31 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* PHASE III CLINICAL STUDY OF DARIDOREXANT HYDROCHLORIDE
TABLETS
FOR INSOMNIA PATIENTS IN CHINA MET PRIMARY ENDPOINT
* PLANS TO SUBMIT A NEW DRUG APPLICATION FOR DARIDOREXANT
HYDROCHLORIDE TABLETS TO NMPA
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660